Non Small Cell Lung Cancer Clinical Trials in Indianapolis, Indiana

13 studies are recruiting for non small cell lung cancer in Indianapolis, Indiana right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

   Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Clinical Study Site, Indianapolis, Indiana

   Locations

   285 in total

   Run by

   Summit Therapeutics

   See if you can join NCT06767514 on ClinicalTrials.gov

2. A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine if telisotuzumab vedotin works better than …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Investigative Clinical Research of Indiana - Indianapolis /ID# 260468, Indianapolis, Indiana

   Locations

   317 in total

   Run by

   AbbVie

   See if you can join NCT04928846 on ClinicalTrials.gov

3. Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

   Prospective clinical study designed to evaluate damage to the heart after receiving standard of care chemotherapy and radiation therapy for locally advanced Non-Small Cell Lung Cancer (NSCLC).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana

   Run by

   Indiana University

   See if you can join NCT07761910 on ClinicalTrials.gov

4. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   IU Simon Cancer Center, Indianapolis, Indiana

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

5. A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

   A study of tolododekin alfa (also known as ANK-101) administered in combination with an anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody in participants with advanced or metastatic non-small cell lung cancer (NSCLC). Cohort A will enroll participants who h…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Community Health Network, Indianapolis, Indiana

   Locations

   11 in total

   Run by

   Ankyra Therapeutics, Inc

   See if you can join NCT07027514 on ClinicalTrials.gov

6. MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

   The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Community Health Network, Indianapolis, Indiana

   Locations

   52 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06586515 on ClinicalTrials.gov

7. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

   This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Community Health Network, Inc, Indianapolis, Indiana

   Locations

   440 in total

   Run by

   Pfizer

   See if you can join NCT07222566 on ClinicalTrials.gov

8. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which ca…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Community Health Network, Inc. /ID# 243011, Indianapolis, Indiana

   Locations

   48 in total

   Run by

   AbbVie

   See if you can join NCT05005403 on ClinicalTrials.gov

9. A Study of VET3-TGI in Patients With Solid Tumors

   VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or whe…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Community Health Network, Indianapolis, Indiana

   Locations

   7 in total

   Run by

   KaliVir Immunotherapeutics

   See if you can join NCT06444815 on ClinicalTrials.gov

10. Repositioning Immunotherapy in VetArans With Lung Cancer

    This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis, Indiana

    Locations

    7 in total

    Run by

    VA Office of Research and Development

    See if you can join NCT06275360 on ClinicalTrials.gov

11. A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

    This study is a Phase 1/2, first-in-human, open-label, clinical trial to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of HMBD-501 in patients with advanced-stage, relapsed and/or refractory human epidermal growth factor receptor 3 (HER3)-expressing solid tumors. The st…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Indianapolis, Indiana

    Locations

    7 in total

    Run by

    Hummingbird Bioscience

    See if you can join NCT06956690 on ClinicalTrials.gov

12. GEMINI-NSCLC: NSCLC Biomarker Study

    GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecul…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Community Health Network, Indianapolis, Indiana

    Locations

    58 in total

    Run by

    Tempus AI

    See if you can join NCT05236114 on ClinicalTrials.gov

13. A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

    This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Community Health Network, Inc., Indianapolis, Indiana

    Locations

    13 in total

    Run by

    GV20 Therapeutics

    See if you can join NCT05669430 on ClinicalTrials.gov